Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,276 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05882370 | TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | recruiting | Phase 2 | 30 | Fei GaoOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06498479 | ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer | recruiting | Phase 3 | 460 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06639971 | Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC(RIO-HCC) | not yet recruiting | — | 500 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06641453 | CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06643533 | Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004) | not yet recruiting | — | 15 | Fujian Provincial HospitalOTHER | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06645314 | Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Early Phase 1 | 16 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT04049214 | Perioperative Mindfulness Proposal | recruiting | N/A | 24 | Hoag Memorial Hospital PresbyterianOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04584008 | Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics(VISIONARY) | active not recruiting | N/A | 600 | Peking UniversityOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05286619 | A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)(PIPER) | recruiting | Phase 2 | 63 | University of MalayaOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT06569498 | Neoadjuvant Triple Therapy for Resectable HCC(TALENP001) | recruiting | — | 20 | Fujian Provincial HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06597513 | Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC | not yet recruiting | Phase 1 / Phase 2 | 10 | Zhou ChengzhiOTHER | 0 | Oct 15, 2024 | clinicaltrials |
| NCT06602011 | Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002) | recruiting | — | 20 | Fujian Provincial HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT06642857 | Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer. | recruiting | — | 150 | Xiangdong ChengOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05440864 | Durvalumab and Tremelimumab in Resectable HCC((NEOTOMA)) | recruiting | Phase 2 | 28 | University Health Network, TorontoOTHER | 3 | Oct 10, 2024 | clinicaltrials |
| NCT06634966 | Segmentectomy for Solid-dominant Lung Cancer | recruiting | Phase 3 | 277 | Fudan UniversityOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05250648 | Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)(GECOP-MMC) | recruiting | Phase 4 | 216 | Hospital Universitario de FuenlabradaOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06623474 | Correlation Study of Lipid Metabolites as Markers of Hepatocellular Carcinoma | recruiting | — | 900 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05766098 | Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY(PTC-ARRAY) | recruiting | — | 600 | Istituto Auxologico ItalianoOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06632093 | HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC | recruiting | — | 84 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT06632106 | HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC | active not recruiting | — | 97 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04571294 | Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy(PALN) | recruiting | N/A | 180 | Humanitas Hospital, ItalyOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06626581 | Iodine Status and Characteristics of Papillary Thyroid Cancer | not yet recruiting | — | 600 | Shandong Provincial HospitalOTHER_GOV | 0 | Oct 4, 2024 | clinicaltrials |
| NCT05495152 | Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 3 | 219 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 2, 2024 | clinicaltrials |
| NCT06624098 | Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma | recruiting | N/A | 22 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2024 | clinicaltrials |
| NCT05797415 | Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers(BLS) | recruiting | — | 25 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06592755 | Single-Incision Gasless Endoscopic Total Thyroidectomy Via Subclavian Approach Versus Open Surgery for PTC | recruiting | — | 120 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06620796 | A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 70 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Oct 1, 2024 | clinicaltrials |
| NCT04117945 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 22 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06247163 | PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.(PET-ART) | recruiting | — | 30 | University Hospital, EssenOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06613269 | 68Ga-NY104 PET/CT Guided Radiation Therapy in CcRCC.(NYCRRT) | recruiting | Phase 2 | 40 | Peking Union Medical College HospitalOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06617000 | A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | recruiting | Phase 1 | 38 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06614621 | A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 26, 2024 | clinicaltrials |
| NCT06259552 | A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors(SPX-303) | recruiting | Phase 1 | 232 | SparX Biotech(Jiangsu) Co., Ltd.OTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06610071 | NIFR Image-guided Surgery for Malignant Soft Tissue Tumor With Low-dose SWIG Technique(NIFR;SWIG) | not yet recruiting | Phase 1 | 592 | The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeOTHER | 0 | Sep 24, 2024 | clinicaltrials |
| NCT05996432 | Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy | recruiting | Early Phase 1 | 48 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06061276 | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC | recruiting | N/A | 40 | Sun Yat-sen UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06464380 | Anti-cancer Potentiality of Saffron Against Hepatocellular Carcinoma | not yet recruiting | Phase 4 | 40 | Ain Shams UniversityOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06607198 | Clinical-pathological Evaluation of Pit-NETs(PitNET2024) | not yet recruiting | — | 940 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT06609070 | CHG0521 Oral Coating in Patients with Solid Tissue Tumor/Recurrent/Metastatic TSCC | not yet recruiting | N/A | 30 | Guangzhou University of Traditional Chinese MedicineOTHER | 0 | Sep 23, 2024 | clinicaltrials |
| NCT04547907 | A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer | recruiting | Phase 3 | 688 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 20, 2024 | clinicaltrials |
| NCT06137378 | European Larynx Organ Preservation Study (ELOS) [MK-3475-C44](ELOS) | recruiting | Phase 2 | 140 | University of LeipzigOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT03454763 | Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors(LUTHREE) | active not recruiting | Phase 2 | 618 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04097470 | Tolerability and Efficacy of Midostaurin to 10-day Decitabine in Unfit Adult AML and High Risk MDS Patients(HO155) | active not recruiting | Phase 2 | 140 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Sep 19, 2024 | clinicaltrials |
| NCT04166006 | A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.(RaC-Ad) | recruiting | Phase 2 | 51 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04718415 | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma(OOC-001) | active not recruiting | Phase 2 | 51 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04951947 | JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer | recruiting | Phase 2 | 30 | Hunan Province Tumor HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04970134 | Spanish Study for Molecular Characterization of Thyroid Carcinoma(MOLTHY) | active not recruiting | — | 150 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 1 | Sep 19, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Oct 16, 2024source: clinicaltrials